Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl-3-substituted-alkyl, aryl or heteroarylamides) as matrix metallo protein inhibitors

A heteroaryl, alkyl technology applied to N-hydroxyl-2-(alkyl, aryl or heteroarylsulfanyl, sulfinyl or sulfonyl)-3- as a matrix metalloproteinase inhibitor The field of substituted alkanes, which can solve the problems of bioavailability and pharmacokinetics, limiting clinical effects, etc.

Inactive Publication Date: 2005-08-03
WYETH HOLDINGS CORP
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although various MMP and TACE inhibitors have been identified and disclosed in the literature, many of these molecules are peptides and peptide analogs that have bioavailability and pharmacokinetic issues that limit their clinical effectiveness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl-3-substituted-alkyl, aryl or heteroarylamides) as matrix metallo protein inhibitors
  • N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl-3-substituted-alkyl, aryl or heteroarylamides) as matrix metallo protein inhibitors
  • N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl-3-substituted-alkyl, aryl or heteroarylamides) as matrix metallo protein inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0225] N-Hydroxy-2-(4-methoxy-phenylsulfanyl)-2-methyl-3-phenyl-propionamide

[0226]To a stirred solution of 4-methoxybenzenethiol (2.8 g, 20 mmol) and anhydrous potassium carbonate (10 g, excess) in anhydrous acetone (100 mL) in a round bottom flask was added 2-bromo-propionic acid ethyl Ester (3.6 g, 20 mmol) and the reaction mixture was heated at reflux for 8 hours with good stirring. Finally, the reaction was cooled and the potassium salt was filtered off, and the above reaction mixture was concentrated. The residue was extracted with chloroform and washed with water and 0.5N sodium hydroxide solution. The organic layer was further washed extensively with water, dried over magnesium sulfate, filtered and concentrated to give ethyl 2-(4-methoxy-phenylsulfanyl)-propionate as a light yellow oil. Yield 4.5 g (94%); MS; 241 (M+H) + .

[0227] To a stirred solution of ethyl 2-(4-methoxy-phenylsulfanyl)-propionate (2.44 g, 10 mmol) in THF (100 ml) at -4°C, bis(trimethyls...

Embodiment 2

[0231] N-Hydroxy-2-(4-methoxy-phenylsulfanyl)-2-phenyl-acetamide

[0232] Ethyl 2-(4-methoxyphenylsulfanyl)-phenylacetate was prepared according to the general procedure described in Example 1. Starting from ethyl [alpha]-bromophenylacetate (7.18 g, 31.4 mmol) and 4-methoxythiophenol (4.4 g, 31.4 mmol), 8.5 g of product were isolated as a pale yellow oil. Yield 90%; MS: 303.1(M+H) + .

[0233] 2-(4-Methoxy-phenylsulfanyl)-phenyl-acetic acid ethyl ester (3.0 g, 10 mmol) was first dissolved in methanol (50 ml) and 10 N sodium hydroxide (20 ml) to prepare 2-( 4-methoxy-phenylsulfanyl)-2-phenylacetic acid. The resulting reaction mixture was worked up as in Example 1. Yield 1.9 g, 70%. Low melting solid. MS: 273(M+H) + .

[0234] Using 2-(4-methoxy-phenylsulfanyl)-2-phenylacetic acid (1.05 g, 3.83 mmol) as raw material, according to the method described in the examples, 154 mg of N-hydroxyl was isolated as a colorless solid -2-(4-Methoxy-phenylsulfanyl)-2-phenyl-ac...

Embodiment 3

[0236] 2-(4-Methoxy-phenylsulfanyl)-2,5-dimethyl-hex-4-enoic acid hydroxyamide

[0237] According to the method in the second paragraph of Example 1, 2-(4-methoxy-phenylsulfanyl)-2,5-dimethyl-hex-4-enoic acid ethyl ester was prepared. Starting from ethyl (4-methoxy-phenylsulfanyl)-propionate (3.5 g, 14.3 mmol) and isoprene bromide (2.25 g, 15 mmol), 2.2 g of product were isolated as an oil . Yield 50%; MS: 310(M+H) + .

[0238] First, ethyl 2-(4-methoxy-phenylsulfanyl)-2,5-dimethyl-hex-4-enoate (2.0 g, 6.4 mmol) was dissolved in methanol (50 ml) and 10N hydrogen 2-(4-Methoxy-phenylsulfanyl)-2,5-dimethyl-hex-4-enoic acid was prepared in sodium oxide (20ml). The resulting reaction mixture was worked up as described in Example 1. Yield of low melting solid 1.9 g, 99%. MS: 28(M+H) + .

[0239] Using 2-(4-methoxy-phenylsulfanyl)-2,5-dimethyl-hex-4-enoic acid (1.67g, 5.8mmol) as raw material, according to the method described in the examples, it was separated to obtain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-alpha converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-alpha from membrane bound TNF-alpha precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-alpha converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R1 and R4 are defined herein.

Description

Background of the invention [0001] Matrix metalloproteinases (MMPs) are a group of enzymes involved in the pathological destruction of connective tissue and basement membrane. These zinc-containing endopeptidases consist of several subtypes of enzymes, including collagenases, stromelysins, and gelatinases. Among these enzymes, gelatinase has been shown to be the MMP enzyme most closely related to the growth and spread of tumors. Gelatinase is known to be expressed at elevated levels in malignant tumors, and gelatinase can degrade basement membranes, leading to tumor metastasis. Angiogenesis required for the growth of solid tumors has also recently been demonstrated to have a gelatinase component in their pathology. Additionally, there is evidence that gelatinase is involved in plaque rupture associated with atherosclerosis. Other diseases mediated by MMPs include restenosis, MMP-mediated osteopenia, central nervous system inflammatory diseases, skin aging, tumor growth, ost...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/16A61K31/351A61K31/381A61K31/403C07D295/08A61K31/4035A61K31/423A61K31/426A61K31/428A61K31/4406A61K31/4418A61K31/4427A61K31/4433A61K31/4436A61K31/445A61K31/4453A61K31/4458A61K31/4535A61K31/454A61K31/4545A61K31/47A61K31/5375A61K31/5377A61K31/55A61P1/02A61P1/04A61P1/16A61P7/02A61P9/00A61P9/10A61P13/12A61P15/06A61P17/00A61P17/02A61P19/02A61P19/08A61P27/02A61P29/00A61P35/00A61P35/04A61P43/00C07C259/06C07C317/44C07C323/60C07D207/12C07D209/48C07D211/12C07D211/20C07D211/54C07D211/62C07D211/66C07D213/56C07D215/12C07D223/02C07D241/04C07D263/58C07D277/20C07D277/36C07D277/70C07D295/092C07D307/54C07D309/12C07D333/28C07D333/34C07D401/10C07D409/04C07D409/10
CPCC07D211/20C07D211/54C07D211/62C07D295/088A61P1/02A61P1/04A61P1/16A61P13/12A61P15/06A61P17/00A61P17/02A61P19/00A61P19/02A61P19/08A61P27/02A61P29/00A61P31/18A61P35/00A61P35/04A61P43/00A61P5/10A61P7/02A61P9/00A61P9/10A61P3/10C07C239/14
Inventor A·M·文卡特桑G·T·格罗苏J·M·达维斯J·L·巴克尔J·I·莱文
Owner WYETH HOLDINGS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com